The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2026 | Cardiac comorbidities in lung cancer: key challenges and approaching treatment decision-making
Gerard M Walls, MB, MRCP, MSc, FRCR, Queens University, Belfast, UK, discusses the challenges of treating lung cancer patients with cardiac comorbidities, highlighting the need for an individualized approach that considers the patient’s overall quality of life, performance status, and other factors beyond just their medical history. Dr Walls emphasizes the importance of using holistic assessments, such as ECOG performance status, 3LD scores, geriatric assessments, sarcopenia assessments, and ePROMs, to determine the best course of treatment for each patient. This interview took place at the 2026 European Lung Cancer Congress in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
